Latest Diasorin News & Updates

See the latest news and media coverage for Diasorin. We track all announcements, press releases, and industry mentions in real time, all in one place.

Diasorin

Immunodiagnostics and molecular diagnostics company

diasorin.com

Headquarters: Saluggia, Italy
Company type: Public company
Number of employees: 2,500–5,000
Industry: Advanced Medical Equipment & Technology

Last updated Today

Latest news about Diasorin

In short: Diasorin reported H1 2026 revenues of €602 million, confirmed its annual guidance, and secured several key FDA clearances for new assays.

Company announcements

July 31 Diasorin

Diasorin's H1 2026 revenue and EBITDA supported by strong Q2 growth

Revenue was €602 million, flat at CER, with adjusted EBITDA of €194 million (32% margin). 2026 guidance confirmed.

June 19 Diasorin

Diasorin receives FDA clearance and CLIA waiver for GAS assay

The assay runs on the LIAISON NES POC platform and delivers molecular results in 15 minutes.

May 20 Diasorin

Diasorin approves 2026-2030 business plan

The plan targets 4-6% CAGR revenue growth and 34-35% EBITDA margin by 2030, focusing on specialty diagnostics expansion.

May 19 Diasorin

Diasorin receives FDA clearance for gastrointestinal assay

The LIAISON PLEX Gastrointestinal Flex Assay detects 24 pathogens and is customizable.

Media coverage

September 3 Repubblica

Technoprobe replaces DiaSorin in the FTSE MIB: tech's weight in the index rises

(Teleborsa) - Technoprobe, a company listed on Euronext Milan and active in the design and production of Probe Cards used for testing semiconductors, will enter...

August 25 Marketscreener

DiaSorin, UBS remains cautious as investors see positive signals | MarketScreener Italy

UBS confirms its negative stance on DiaSorin, maintaining a 'sell' recommendation and a target price of EUR55.00, compared to the EUR75.00 recorded by the stock...

August 12 Il Sole 24 Ore

Diasorin downgraded to 'sell', according to Ubs competitive pressures rise - Il Sole 24 ORE

(Il Sole 24 Ore Radiocor) - Diasorin slides on Piazza Affari (FTSE MIB) after the downgrade by Ubs analysts, who have revised...

August 12 Milano Finanza

MARKET DRIVER: Diasorin -3.5%, UBS lowers rating

MILAN (MF-NW)--UBS has lowered its recommendation on Diasorin (-3.45% at 73.94 euros) from neutral to sell, with a target price that goes from 66 to 55...

Never miss news about Diasorin

Track Diasorin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Diasorin competitors & trending companies

Browse news for competitors to Diasorin and other trending companies.